For the first time, privately-owned Stada has acknowledged the potential for a sale of the business – six years after the private equity duo Bain Capital and Cinven announced a deal worth upwards of €5.4bn for the German firm.
Bain Capital and Cinven are considering the possibility of selling STADA Arzneimittel AG, the company’s CEO Peter Goldschmidt has acknowledged, almost exactly six years to the day since the private equity duo took control of the Germany-based, European generics and biosimilars giant.
Goldschmidt’s comments, made to the German Press Agency, follow reports in Bloomberg earlier this month that Bain and Cinven were mulling a potential sale valuing Stada at around €10bn ($10.1bn)
The Belgian value-added medicines specialist company struck two commercialization deals over its novel valacyclovir oral suspension that span three continents, marking a further milestone in the product’s development.
A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.
Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.
Apotex has expanded an alliance formed with Formosa in August for its novel clobetasol propionate ophthalmic treatment, adding Mexican rights to its existing deal for the Canadian market.
A free trade agreement struck between the UK and India could over “significant benefits for the generic and biosimilar sectors,” Medicines UK believes. The off-patent industry association has also suggested further avenues for collaboration between the two governments on regulatory pathways and supply security.
Teva underlined that it was “very pleased with this franchise we’re building and what we’ll bring to the care of patients with schizophrenia,” as it looks ahead to filing its olanzapine new drug application in the second half of 2025.
Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.
